BACKGROUND: To observe the anti-tumor effects and possible mechanism of C21 steroidal glycoside (17-β-Marsdenia tenacissima glycoside B (17-β-tenacigenin B)) and Xiaoaiping injection in the adenoid cystic carcinoma cell line SACC83. METHODS: We used the salivary adenoid cystic carcinoma cell line SACC83 for the study and used MTT, flow cytometry, and Western-blot (WB) to study the anti-tumor efficacy and mechanism of 17-β-tenacigenin B and Xiaoaiping injection. Three groups were divided as follows: group 1: control group (without drug treatment), group 2: SACC83 treated with 17-β-Marsdenia tenacissima glycoside B, group 3: SACC83 treated with Xiaoaiping injec- tion. RESULTS: The 17-β-tenacigenin B had no significant anti-tumor effect while the Xiaoaiping injection had a dosage-dependent growth inhibition effect on the adenoid cystic carcinoma cell line SACC83. According to WB, after the administration of the 17-p-tenacigenin B, the expression of apoptosis-related protein was not very significant; however, after the administration of the Xiaoaiping injection, the expression of apoptosis inhibition protein bcl-2 decreased while the expression of apoptosis promotion protein bax increased. CONCLUSIONS: The 17-β-tenacigenin B had no obvious anti-tumor effects while the Xiaoaiping injection had good anti-tumor effects. Even though the 17-β-tenacigenin B is an important component of the Xiaoaiping injection, in the in vitro experiment, compared with the Xiaoaiping injection, the 17-β-tenacigenin B showed no good anti-tumor effects. However, we need further studies on in vivo experiments of 17-β-tenacigenin B and the anti-tumor effect of other C21 steroidal glycoside monomers in the Xiaoaiping injection.
BACKGROUND: To observe the anti-tumor effects and possible mechanism of C21 steroidal glycoside (17-β-Marsdenia tenacissimaglycoside B (17-β-tenacigenin B)) and Xiaoaiping injection in the adenoid cystic carcinoma cell line SACC83. METHODS: We used the salivary adenoid cystic carcinoma cell line SACC83 for the study and used MTT, flow cytometry, and Western-blot (WB) to study the anti-tumor efficacy and mechanism of 17-β-tenacigenin B and Xiaoaiping injection. Three groups were divided as follows: group 1: control group (without drug treatment), group 2: SACC83 treated with 17-β-Marsdenia tenacissimaglycoside B, group 3: SACC83 treated with Xiaoaiping injec- tion. RESULTS: The 17-β-tenacigenin B had no significant anti-tumor effect while the Xiaoaiping injection had a dosage-dependent growth inhibition effect on the adenoid cystic carcinoma cell line SACC83. According to WB, after the administration of the 17-p-tenacigenin B, the expression of apoptosis-related protein was not very significant; however, after the administration of the Xiaoaiping injection, the expression of apoptosis inhibition protein bcl-2 decreased while the expression of apoptosis promotion protein bax increased. CONCLUSIONS: The 17-β-tenacigenin B had no obvious anti-tumor effects while the Xiaoaiping injection had good anti-tumor effects. Even though the 17-β-tenacigenin B is an important component of the Xiaoaiping injection, in the in vitro experiment, compared with the Xiaoaiping injection, the 17-β-tenacigenin B showed no good anti-tumor effects. However, we need further studies on in vivo experiments of 17-β-tenacigenin B and the anti-tumor effect of other C21 steroidal glycoside monomers in the Xiaoaiping injection.